Does Entresto (sacubitril/valsartan) increase B-type natriuretic peptide (BNP) levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Does Entresto Increase BNP?

Yes, Entresto (sacubitril/valsartan) does increase BNP levels, but the effect is variable and unpredictable across patients. 1

Mechanism and Clinical Evidence

Entresto's neprilysin inhibition component (sacubitril) blocks the enzyme that normally degrades BNP, leading to accumulation of this peptide in circulation. The FDA label explicitly states that in the PARADIGM-HF trial, Entresto increased plasma BNP (a neprilysin substrate) compared with enalapril 1. This is a direct pharmacodynamic consequence of neprilysin inhibition.

Magnitude and Variability of BNP Increase

The increase in BNP is highly variable between patients:

  • Average increase: 19% after treatment initiation 2
  • 18% of patients experience BNP doubling
  • 6% of patients experience BNP tripling
  • 14% of patients show no change at all 2

This heterogeneity is clinically important because it means you cannot predict how an individual patient's BNP will respond. The guideline evidence from JACC: Heart Failure (2020) emphasizes this rightward shift in BNP distribution is caused by treatment with sacubitril/valsartan 2.

Critical Clinical Distinction: BNP vs NT-proBNP

NT-proBNP is NOT a substrate for neprilysin and therefore decreases with Entresto treatment 3, 1. This creates a crucial clinical scenario:

  • BNP increases (or remains elevated/variable)
  • NT-proBNP decreases by 30-32% at weeks 4-12 4

The FDA label confirms that in PARADIGM-HF, Entresto decreased plasma NT-proBNP (not a neprilysin substrate) while increasing plasma BNP 1.

Clinical Implications for Monitoring

If Using BNP for Monitoring:

  1. Expect an increase or at minimum no decrease in the first 8-10 weeks after starting Entresto
  2. BNP remains prognostically valid despite the increase - higher levels still predict worse outcomes 5
  3. Rising BNP during treatment indicates worsening disease, not just drug effect 2
  4. Assay variability matters - different BNP assays show inconsistent responses to neprilysin inhibition 6

If Using NT-proBNP for Monitoring (Preferred):

  1. NT-proBNP should decrease with successful Entresto therapy
  2. Less clinical confusion since it's not affected by neprilysin inhibition 3, 2
  3. More predictable interpretation in the first 8-10 weeks of treatment 5

Common Pitfalls to Avoid

Do not interpret an elevated or rising BNP in the first 8-10 weeks of Entresto as treatment failure. This is the most common error. The increase reflects neprilysin inhibition working as intended, not worsening heart failure 2, 5.

Do not switch between BNP and NT-proBNP assays during Entresto treatment - they move in opposite directions, creating confusion 1.

Do not assume all patients will have BNP increases - 14% show no change, making individual patient responses unpredictable 2.

Prognostic Value Remains Intact

Despite the pharmacologic increase in BNP, both BNP and NT-proBNP retain their prognostic accuracy during Entresto treatment (C-statistics 63-67% for BNP, 64-70% for NT-proBNP) 5. Increases in either peptide during treatment are associated with worse outcomes, indicating true disease progression rather than just drug effect 5.

Bottom Line for Practice

Use NT-proBNP for monitoring patients on Entresto - it decreases with successful therapy and avoids the clinical confusion of BNP increases 3, 2. If your institution only measures BNP, establish a baseline steady-state concentration after 8-10 weeks of treatment and use the same assay consistently for serial monitoring 5, 7. Rising BNP after this stabilization period indicates worsening heart failure and warrants clinical action.

Related Questions

In a patient receiving Entresto (sacubitril/valsartan), is B-type natriuretic peptide (BNP) an unreliable marker for assessing heart‑failure severity?
For a patient on Entresto (sacubitril/valsartan), is ordering NT‑proBNP (proBNP) the correct laboratory test?
What NT‑proBNP level thresholds indicate use of Entresto (sacubitril/valsartan) in patients with symptomatic heart failure with reduced ejection fraction?
Does Entresto (sacubitril/valsartan) have a diuretic effect?
In a patient with heart failure on sacubitril/valsartan, metoprolol, and hydrochlorothiazide who presents with fatigue, occasional vomiting, and wheezing, is fluid overload likely?
What is the recommended pediatric dose of Montair LC syrup (montelukast 4 mg/levocetirizine 2.5 mg per 5 mL) for children aged 2 to 14 years?
Is there a correlation between nightmares and metoprolol use?
What is the recommended starting dose and titration schedule for Lotrel (amlodipine/benazepril) in an adult with uncomplicated hypertension, and how should the dose be adjusted for patients with eGFR <30 mL/min or who are ACE‑inhibitor naïve?
What are the indications for urodeoxycholic acid 300 mg tablets, and is long‑term use safe in alcoholic liver disease?
Is it safe for a patient taking Mounjaro (tirzepatide) who has a history of thyroid cancer and has undergone thyroidectomy to continue this medication?
A patient presents with ankle edema, erythema, and warmth; should they be managed as an outpatient or referred to the emergency department for urgent evaluation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.